• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tactile Medical Announces New Appointments to Board of Directors

    1/5/22 4:05:00 PM ET
    $JNJ
    $ORCL
    $PHG
    $TCMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $JNJ alert in real time by email

    MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the appointment of Valerie L. Asbury and D. Brent Shafer to the Company's Board of Directors ("Board"), effective January 5, 2022. Ms. Asbury will serve as a member of both the Audit Committee and the Compliance & Reimbursement Committee. Mr. Shafer will serve as a member of the Audit Committee, the Compensation & Organization Committee, and the Nominating & Corporate Governance Committee. Three long-standing directors will be retiring from the Board ahead of the May shareholder meeting: Peter Soderberg, Richard Nigon and Kevin Roche.

    "We are extremely pleased to welcome Valerie and Brent to our Board; both experienced leaders, adding depth of expertise in the treatment of chronically ill patients and channels to access and support them," said Bill Burke, Chairman of the Board of Tactile Medical. "I would also like to extend my sincere gratitude to Peter, Dick and Kevin for their dedicated years of service. Their counsel and oversight played an important role in helping Tactile Medical become a successful company, eclipsing $200 million in annual revenue."

    Since 2018, Valerie Asbury has served as the President and CEO of LifeScan, a global leader in blood glucose monitoring, serving more than 20 million people with diabetes. Ms. Asbury previously held a series of leadership roles within Johnson & Johnson (NYSE:JNJ) for over 20 years from 1998 to 2018, including executive sales and general management positions. Her most recent position at Johnson & Johnson was Global President of Diabetes Solutions from 2013 to 2018, including the Global LifeScan subsidiary until its sale in October 2018 to Platinum Equity, a leading private investment firm. She holds a Bachelor of Science in Nursing from Vanderbilt University.

    Brent Shafer most recently served as Chairman and CEO of Cerner Corporation from 2018 until September 2021, a global healthcare technology company that was acquired by Oracle Corporation (NYSE:ORCL) in December 2021. Prior to Cerner, Mr. Shafer was Chief Executive Officer of Philips North America, a health technology company and the North American division of Koninklijke Philips N.V. (("Philips", NYSE:PHG, AEX: PHIA)), from 2014 to 2018. Mr. Shafer also served as Chief Executive Officer of the global Philips' Home Healthcare Solutions business from 2010 until 2014. Mr. Shafer previously held a series of leadership roles at Philips, Hill Rom and GE Healthcare. He holds a Bachelor of Science from the University of Utah.

    About Tactile Medical

    Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.  



    Investor Inquiries:
    Mike Piccinino, CFA
    Managing Director
    ICR Westwicke
    [email protected]

    Primary Logo

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JNJ
    $ORCL
    $PHG
    $TCMD

    CompanyDatePrice TargetRatingAnalyst
    Oracle Corporation
    $ORCL
    7/2/2025$235.00 → $245.00Outperform
    BMO Capital Markets
    Oracle Corporation
    $ORCL
    6/30/2025$250.00Hold → Buy
    Stifel
    Oracle Corporation
    $ORCL
    6/18/2025$220.00 → $250.00Buy
    Guggenheim
    Oracle Corporation
    $ORCL
    6/13/2025$235.00Market Perform → Outperform
    BMO Capital Markets
    Oracle Corporation
    $ORCL
    6/9/2025$175.00 → $200.00Market Perform
    BMO Capital Markets
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Tactile Systems Technology Inc.
    $TCMD
    5/6/2025$14.00Overweight → Neutral
    Piper Sandler
    Oracle Corporation
    $ORCL
    4/23/2025$130.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $JNJ
    $ORCL
    $PHG
    $TCMD
    SEC Filings

    See more
    • SEC Form 8-K filed by Oracle Corporation

      8-K - ORACLE CORP (0001341439) (Filer)

      6/30/25 8:30:26 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 144 filed by Oracle Corporation

      144 - ORACLE CORP (0001341439) (Subject)

      6/27/25 4:13:03 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 144 filed by Oracle Corporation

      144 - ORACLE CORP (0001341439) (Subject)

      6/26/25 4:17:06 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BMO Capital Markets reiterated coverage on Oracle with a new price target

      BMO Capital Markets reiterated coverage of Oracle with a rating of Outperform and set a new price target of $245.00 from $235.00 previously

      7/2/25 8:04:33 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Oracle upgraded by Stifel with a new price target

      Stifel upgraded Oracle from Hold to Buy and set a new price target of $250.00

      6/30/25 7:56:35 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Guggenheim reiterated coverage on Oracle with a new price target

      Guggenheim reiterated coverage of Oracle with a rating of Buy and set a new price target of $250.00 from $220.00 previously

      6/18/25 9:35:56 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Pinto Daniel E claimed no ownership of stock in the company (SEC Form 3)

      3 - JOHNSON & JOHNSON (0000200406) (Issuer)

      7/8/25 5:31:26 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Accounting Officer Smith Maria sold $2,329,897 worth of shares (10,000 units at $232.99), decreasing direct ownership by 20% to 40,807 units (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      7/8/25 4:44:10 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Chief Executive Officer Catz Safra exercised 1,260,508 shares at a strike of $51.13 and sold $267,244,339 worth of shares (1,260,508 units at $212.01) (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      7/1/25 5:10:59 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tactile Systems Technology Inc.

      SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/13/24 7:29:11 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tactile Systems Technology Inc.

      SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/13/24 5:04:27 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tactile Systems Technology Inc.

      SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/8/24 3:21:42 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oracle Database@AWS Now Generally Available

      Customers can now use Oracle Database@AWS in AWS Regions in Northern Virginia and Oregon, with planned expansion to 20 more  Enterprises including Fidelity Investments, Nationwide, and SAS are adopting Oracle Database@AWS to migrate and run Oracle Exadata Database Service and Oracle Autonomous Database on OCI within AWS  AUSTIN, Texas and SEATTLE, July 8, 2025 /PRNewswire/ -- Oracle and Amazon Web Services, Inc. (AWS) today announced the general availability of Oracle Database@AWS. Customers can now run Oracle Exadata Database Service and Oracle Autonomous Database on dedicated infrastructure on Oracle Cloud Infrastructure (OCI) within AWS. Oracle Database@AWS is available in the AWS U.S. Ea

      7/8/25 8:00:00 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

      Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA® is FDA approved to treat schizophrenia and is the first and only approved treatment for bipolar I and II depression as an adjunctive and monotherapy With the addition of CAPLYTA® to Johnson & Johnson's robust portfolio of therapies, the Company now offers the broadest range of treatment options for adults with schizophrenia   TITUSVILLE, N.J., July 8, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based upon lon

      7/8/25 8:00:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PrimeVigilance Enhances Efficiency and Patient Safety with Oracle Argus Platform

      Contract Research Organization aims to improve data management, accuracy, and safety with Oracle's AI-powered pharmacovigilance platform AUSTIN, Texas, July 8, 2025 /PRNewswire/ -- Contract Research Organization (CRO), PrimeVigilance, is significantly enhancing its service offerings with Oracle Argus. Delivering the full lifecycle of pharmacovigilance services, the CRO is leveraging Argus to provide its clients with a powerful, AI-driven solution to help optimize their drug development programs and support patient safety and regulatory compliance. PrimeVigilance is part of the Ergomed Group whose mission is to deliver leading solutions that support its customers' clinical projects to speed t

      7/8/25 8:00:00 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Boskin Michael J bought $111,145 worth of shares (1,682 units at $66.08), increasing direct ownership by 2% to 92,458 units (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      3/21/25 8:43:30 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Director Moorman Charles W bought $947,913 worth of shares (5,500 units at $172.35) (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      2/14/25 4:41:16 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Leadership Updates

    Live Leadership Updates

    See more
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

      Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

      6/10/25 4:51:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Philips shareholders approve all proposals at the AGM 2025

      May 8, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2025, including: The re-appointment of Ms Indra Nooyi and Ms Chua Sock Koong as members of the Supervisory Board.The appointment of Mr Bob White as a new member of the Supervisory Board.The re-appointment of Mr Marnix van Ginneken as member of the Board of Management. The discharge of the members of the Board of Management, and of the members of the Supervisory Board.A full overview of the resolutions taken at the AGM 2025 can be found below. Feike Sijbesma, Chairman of Philips' Supervisory Board, sa

      5/8/25 12:16:51 PM ET
      $PHG
      Medical Electronics
      Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Financials

    Live finance-specific insights

    See more
    • Oracle Announces Fiscal 2025 Fourth Quarter and Fiscal Full Year Financial Results

      Q4 Remaining Performance Obligations up 41% to $138 billionQ4 GAAP Earnings per Share $1.19, non-GAAP Earnings per Share $1.70Q4 Total Revenue $15.9 billion, up 11%Q4 Cloud Revenue (IaaS plus SaaS) $6.7 billion, up 27%Q4 Cloud Infrastructure (IaaS) Revenue $3.0 billion, up 52%Q4 Cloud Application (SaaS) Revenue $3.7 billion, up 12%Q4 Fusion Cloud ERP (SaaS) Revenue $1.0 billion, up 22%Q4 NetSuite Cloud ERP (SaaS) Revenue $1.0 billion, up 18%FY 2025 Total Revenue $57.4 billion, up 8%AUSTIN, Texas, June 11, 2025 /PRNewswire/ -- Oracle Corporation (NYSE:ORCL) today announced fiscal 2025 Q4 and full-year 2025 results. Total quarterly revenues were up 11% year-over-year in USD and constant curren

      6/11/25 4:05:00 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Philips announces exchange ratio for 2024 dividend

      June 5, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, and 3, 2025, of EUR 20.0600 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 22,980,748 new common shares. Shareholders have been given the opportunity to make their choice between a dividend in shares or (subject to certain conditions) in cash. The aggregate cash election

      6/5/25 4:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Oracle Sets the Date for its Fourth Quarter Fiscal Year 2025 Earnings Announcement

      Earnings Results to be released on June 11, 2025, After the Close of the Market AUSTIN, June 3, 2025 /PRNewswire/ -- Oracle Corporation today announced that its fourth quarter and fiscal year 2025 results will be released on Wednesday, June 11th, after the close of the market.  Oracle will host a conference call and live webcast at 4:00 p.m. Central Time to discuss the financial results.  The live webcast will be available on the Oracle Investor Relations website at www.oracle.com/investor. About Oracle Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE:ORCL), please visit us at www.oracle.com.

      6/3/25 4:00:00 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology